In January 2026, Calcium Acetate markets in China firmed on seasonal buying and tight upstream availability. Municipal tenders and year-start budgets supported steady offtake, while domestic pharmaceutical formulators accelerated purchases ahead of the Lunar New Year. Export demand from India, Vietnam, and the United States remained robust, keeping orderbooks healthy. Winter peak heating pressures on coal and power tariffs, plus unannounced environmental audits, constrained some local output and encouraged cautious restocking rather than broad speculative buying. Demand was uneven across end-use segments, but the tone remained positive. The pharmaceutical sector remained strongest, with formulators booking ahead for excipients and pharmaceutical-grade Calcium Acetate, lifting spot offers. In contrast, dye-intermediate and textile demand weakened. Upstream costs rose, and environmental inspections trimmed supply modestly. The near-term view anticipates easing in February with gradual restocking through spring, contingent on feedstock dynamics.
